AU2012308681B2 - Aminopyrimidine derivatives for use as modulators of kinase activity - Google Patents

Aminopyrimidine derivatives for use as modulators of kinase activity Download PDF

Info

Publication number
AU2012308681B2
AU2012308681B2 AU2012308681A AU2012308681A AU2012308681B2 AU 2012308681 B2 AU2012308681 B2 AU 2012308681B2 AU 2012308681 A AU2012308681 A AU 2012308681A AU 2012308681 A AU2012308681 A AU 2012308681A AU 2012308681 B2 AU2012308681 B2 AU 2012308681B2
Authority
AU
Australia
Prior art keywords
amino
piperazin
phenyl
obsd
title compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2012308681A
Other languages
English (en)
Other versions
AU2012308681A1 (en
Inventor
Xiaoling Chen
Lizbeth Celeste DESELM
Bayard R. Huck
Theresa L. Johnson
Rouxi Lan
Igor Mochalkin
Constantin Neagu
Hui QIU
Yufang Xiao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of AU2012308681A1 publication Critical patent/AU2012308681A1/en
Application granted granted Critical
Publication of AU2012308681B2 publication Critical patent/AU2012308681B2/en
Priority to AU2017245469A priority Critical patent/AU2017245469B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C07D239/49—Two nitrogen atoms with an aralkyl radical, or substituted aralkyl radical, attached in position 5, e.g. trimethoprim
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2012308681A 2011-09-12 2012-09-12 Aminopyrimidine derivatives for use as modulators of kinase activity Ceased AU2012308681B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017245469A AU2017245469B2 (en) 2011-09-12 2017-10-09 Aminopyrimidine derivatives for use as modulators of kinase activity

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161533606P 2011-09-12 2011-09-12
US61/533,606 2011-09-12
PCT/US2012/054877 WO2013040044A1 (en) 2011-09-12 2012-09-12 Aminopyrimidine derivatives for use as modulators of kinase activity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017245469A Division AU2017245469B2 (en) 2011-09-12 2017-10-09 Aminopyrimidine derivatives for use as modulators of kinase activity

Publications (2)

Publication Number Publication Date
AU2012308681A1 AU2012308681A1 (en) 2014-02-27
AU2012308681B2 true AU2012308681B2 (en) 2017-07-13

Family

ID=46964039

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2012308681A Ceased AU2012308681B2 (en) 2011-09-12 2012-09-12 Aminopyrimidine derivatives for use as modulators of kinase activity
AU2017245469A Ceased AU2017245469B2 (en) 2011-09-12 2017-10-09 Aminopyrimidine derivatives for use as modulators of kinase activity

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017245469A Ceased AU2017245469B2 (en) 2011-09-12 2017-10-09 Aminopyrimidine derivatives for use as modulators of kinase activity

Country Status (24)

Country Link
US (3) US9321760B2 (OSRAM)
EP (1) EP2755958B9 (OSRAM)
JP (1) JP6082011B2 (OSRAM)
KR (1) KR101992505B1 (OSRAM)
CN (2) CN103930407B (OSRAM)
AU (2) AU2012308681B2 (OSRAM)
BR (1) BR112014005468A2 (OSRAM)
CA (1) CA2844704C (OSRAM)
DK (1) DK2755958T3 (OSRAM)
EA (1) EA028057B1 (OSRAM)
ES (1) ES2646759T3 (OSRAM)
HR (1) HRP20171655T1 (OSRAM)
HU (1) HUE034979T2 (OSRAM)
IL (2) IL231381B (OSRAM)
LT (1) LT2755958T (OSRAM)
MX (1) MX347241B (OSRAM)
NO (1) NO2639780T3 (OSRAM)
PL (1) PL2755958T3 (OSRAM)
PT (1) PT2755958T (OSRAM)
RS (1) RS56486B1 (OSRAM)
SG (1) SG2014009260A (OSRAM)
SI (1) SI2755958T1 (OSRAM)
WO (1) WO2013040044A1 (OSRAM)
ZA (1) ZA201401007B (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101880966B1 (ko) * 2011-06-10 2018-07-23 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
MX347241B (es) * 2011-09-12 2017-04-20 Merck Patent Gmbh Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
CA2890288A1 (en) 2012-11-16 2014-05-22 Merck Patent Gmbh Novel heterocyclic derivatives as modulators of kinase activity
AU2014228385B2 (en) 2013-03-11 2018-08-09 Merck Patent Gmbh 6-[4-(1-H-imidazol-2-yl]piperidin-1 -yl]pyrimidin-4-amine derivatives as modulators of kinase activity
JP6473457B2 (ja) 2014-01-17 2019-02-20 ノバルティス アーゲー Ｓｈｐ２の活性を阻害するための１−（トリアジン−３−イル／ピリダジン−３−イル）−ピペリジン／ピペラジン誘導体およびその組成物
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
US10093646B2 (en) 2014-01-17 2018-10-09 Novartis Ag 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2
EP3105224A1 (en) * 2014-02-11 2016-12-21 Merck Patent GmbH Pyrimidine imidazole amines as modulators of kinase activity
EP2939514B1 (en) 2014-04-30 2018-09-05 LG Electronics Inc. Lawn mower robot and control method thereof
CN106661033B (zh) * 2014-05-28 2018-11-06 阿斯利康(瑞典)有限公司 用于制备azd5363的方法和在其中使用的新颖中间体
CN107922388B (zh) 2015-06-19 2020-12-29 诺华股份有限公司 用于抑制shp2活性的化合物和组合物
EP3310779B1 (en) 2015-06-19 2019-05-08 Novartis AG Compounds and compositions for inhibiting the activity of shp2
ES2824576T3 (es) 2015-06-19 2021-05-12 Novartis Ag Compuestos y composiciones para inhibir la actividad de SHP2
WO2017019804A2 (en) 2015-07-28 2017-02-02 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
ES2904615T3 (es) * 2016-03-16 2022-04-05 Plexxikon Inc Compuestos y métodos para la modulación de quinasas e indicaciones al respecto
PT3468972T (pt) 2016-06-14 2020-08-21 Novartis Ag Compostos e composições para inibir a atividade da shp2
JP7503380B2 (ja) 2017-01-10 2024-06-20 ノバルティス アーゲー Ａｌｋ阻害剤およびｓｈｐ２阻害剤を含む組合せ医薬
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
EP3710001B1 (en) 2017-10-27 2025-06-18 University Of Virginia Patent Foundation Compounds and methods for regulating, limiting, or inhibiting avil expression
EP3962485A4 (en) * 2019-05-02 2022-12-28 University Of Virginia Patent Foundation SUBSTITUTED (PIPERIDINE-1-YL)ARYL ANALOGUES TO MODULATE AVILACTIVITY
US11866421B2 (en) 2021-05-31 2024-01-09 Epigen Biosciences, Inc. Pyrimidine and pyridine amine compounds and usage thereof in disease treatment

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130954A1 (en) * 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
WO2006071819A1 (en) * 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2008075172A2 (en) * 2006-12-19 2008-06-26 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137755A1 (en) * 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
JP2006522124A (ja) 2003-04-03 2006-09-28 バーテックス　ファーマシューティカルズ　インコーポレイテッド プロテインキナーゼのインヒビターとして有用な組成物
EP1670771A4 (en) 2003-09-30 2010-09-01 Irm Llc COMPOUNDS AND COMPOSITIONS INHIBITING PROTEIN-KINASES
WO2005039506A2 (en) 2003-10-24 2005-05-06 Exelixis, Inc. P70s6 kinase modulators and method of use
BRPI0416801A (pt) 2003-11-21 2007-01-09 Novartis Ag derivados de 1h-imidazoquinolina como inibidores de proteìna sinase
KR20060123463A (ko) 2003-12-09 2006-12-01 더 거번먼트 오브 더 유나이티드 스테이츠 오브 어메리카 애즈 레프리젠티드 바이 더 세크러터리 오브 더 디파트먼트 오브 헬쓰 앤드 휴먼 써비시즈 면역 반응을 억제하거나 증식성 장애를 치료하는 방법들
US8076338B2 (en) 2004-04-23 2011-12-13 Exelixis, Inc. Kinase modulators and methods of use
WO2006078992A2 (en) 2005-01-19 2006-07-27 Neurogen Corporation Heteroaryl substituted piperazinyl-pyridine analogues
GB0501999D0 (en) 2005-02-01 2005-03-09 Sentinel Oncology Ltd Pharmaceutical compounds
US8343953B2 (en) 2005-06-22 2013-01-01 Astex Therapeutics Limited Pharmaceutical compounds
EP3719018B1 (en) * 2006-04-25 2025-08-27 Astex Therapeutics Ltd Purine and deazapurine derivatives as pharmaceutical compounds
WO2008012635A2 (en) * 2006-07-26 2008-01-31 Pfizer Products Inc. Amine derivatives useful as anticancer agents
WO2008061108A2 (en) * 2006-11-15 2008-05-22 Forest Laboratories Holdings Limited Phthalazine derivatives
UA99284C2 (ru) 2007-05-11 2012-08-10 Елі Ліллі Енд Компані ИНГИБИТОРЫ р70 S6-КИНАЗЫ
AR074072A1 (es) 2008-11-11 2010-12-22 Lilly Co Eli Compuesto de imidazol -piperidin -pirrol-pirimidin-6-ona, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar el glioblastoma multiforme
EP2396307B1 (en) 2009-02-11 2014-10-15 Merck Patent GmbH Novel amino azaheterocyclic carboxamides
WO2011029043A1 (en) * 2009-09-04 2011-03-10 Biogen Idec Ma Inc. Heteroaryl btk inhibitors
UA110113C2 (xx) 2010-07-29 2015-11-25 Біциклічні азагетероциклічні карбоксаміди
CA2803387C (en) 2010-07-29 2017-12-05 Bayard R. Huck Cyclic amine azaheterocyclic carboxamides
SI2643313T1 (sl) 2010-11-24 2016-11-30 Merck Patent Gmbh Kinazolin-karboksamidni azetidini
EP2755965B1 (en) * 2011-09-12 2017-07-26 Merck Patent GmbH Novel imidazole amines as modulators of kinase activity
MX347241B (es) * 2011-09-12 2017-04-20 Merck Patent Gmbh Derivados de aminopirimidina para usarse como moduladores de la actividad de cinasa.
ES2656096T3 (es) * 2012-11-16 2018-02-23 Merck Patent Gmbh Nuevos derivados de imidazol-piperidinilo como moduladores de la actividad de quinasa
EP3105224A1 (en) * 2014-02-11 2016-12-21 Merck Patent GmbH Pyrimidine imidazole amines as modulators of kinase activity

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050130954A1 (en) * 2003-11-21 2005-06-16 Mitchell Ian S. AKT protein kinase inhibitors
WO2006071819A1 (en) * 2004-12-28 2006-07-06 Exelixis, Inc. [1h-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-theoronine kinase modulators (p70s6k, atk1 and atk2) for the treatment of immunological, inflammatory and proliferative diseases
WO2008075172A2 (en) * 2006-12-19 2008-06-26 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
C. BARILLARI ET AL, ‘Solid Phase Synthesis of Diamino-Substituted Pyrimidines’, EUR. J. ORG. CHEM., 1 January 2001 pages 4737-4741 *
Chemical Abstracts Accession No. 1982:199633 *

Also Published As

Publication number Publication date
US20170217905A1 (en) 2017-08-03
IL231381B (en) 2019-05-30
CA2844704A1 (en) 2013-03-21
EA201400338A1 (ru) 2014-12-30
US9321760B2 (en) 2016-04-26
MX2014002836A (es) 2014-05-28
PT2755958T (pt) 2017-11-14
JP2014527082A (ja) 2014-10-09
AU2012308681A1 (en) 2014-02-27
CN106946796A (zh) 2017-07-14
IL231381A0 (en) 2014-04-30
WO2013040044A1 (en) 2013-03-21
SG2014009260A (en) 2014-09-26
IL266510A (en) 2019-07-31
CA2844704C (en) 2020-04-28
HK1198168A1 (en) 2015-03-13
US9662330B2 (en) 2017-05-30
US20160184308A1 (en) 2016-06-30
LT2755958T (lt) 2017-11-10
HRP20171655T1 (hr) 2017-12-15
US20150126484A1 (en) 2015-05-07
KR101992505B1 (ko) 2019-06-24
HUE034979T2 (en) 2018-05-02
AU2017245469B2 (en) 2019-05-23
IL266510B (en) 2021-01-31
MX347241B (es) 2017-04-20
BR112014005468A2 (pt) 2017-03-21
US10080750B2 (en) 2018-09-25
EP2755958B1 (en) 2017-08-09
RS56486B1 (sr) 2018-01-31
DK2755958T3 (en) 2017-09-25
CN103930407B (zh) 2019-02-26
ES2646759T3 (es) 2017-12-15
JP6082011B2 (ja) 2017-02-15
AU2017245469A1 (en) 2017-11-02
PL2755958T3 (pl) 2017-12-29
CN106946796B (zh) 2020-05-08
EA028057B1 (ru) 2017-10-31
EP2755958A1 (en) 2014-07-23
SI2755958T1 (sl) 2017-12-29
NO2639780T3 (OSRAM) 2018-06-23
KR20140062494A (ko) 2014-05-23
ZA201401007B (en) 2018-07-25
CN103930407A (zh) 2014-07-16
EP2755958B9 (en) 2018-02-28

Similar Documents

Publication Publication Date Title
AU2012308681B2 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
CA2818706C (en) Quinazoline carboxamide azetidines
US9145392B2 (en) Imidazole amines as modulators of kinase activity
CN113993866A (zh) 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
CA2902755C (en) 6-[4-(1h-imidazol-2-yl)piperidin-1-yl]pyrimidin-4-amine derivatives as modulators of kinase activity
HK1240220A1 (en) Aminopyrimidine derivatives for use as modulators of kinase activity
HK1198168B (zh) 用作激酶活性调节剂的氨基嘧啶衍生物

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired